I expect that Gleevec will remain the tyrosine kinase inhibitor of choicee in first-line CML until data from Tasigna and or Sprycel will show superiority in OS.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.